For #NephJC discussion this week: should we be treating inpatient hypertension (with IV Hydralazine right @ChristosArgyrop ?)

http://www.nephjc.com/news/inpatient-hypertension

@KidneyVet ping #NephJC #MedMastodon

Balanced solutions in #kidney #transplant

The BEST FLUIDS trial for this week’s #NephJC http://www.nephjc.com/news/bestfluids

➡️ Next #NephJC Chat is 🥁

'Intravenous Sodium Thiosulphate for Calciphylaxis of Chronic Kidney Disease: Systematic Review and Meta-analysis'
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804210

Join us on June 20th and 21st 📢

#TenTweetNephJC by @SayaliBThakare brought to med-mastodon by @jmteakell :)

The #NSMC never sleeps by Momen Abbasi 👇

10/10
#NephJC 10 Toot Final thoughts

Sparsentan (FILSPARI) holds promise.
➡️Convincing biological plausibility
➡️Favourable reduction in proteinuria
➡️Early onset effect
➡️Comparable side-effect profile
➡️Safety in study group (though carefully selected)

"Hope is a good thing, maybe the best!"

9/10
I want more info:

🪶#NephJC summary by Anitha Swamy & Saumya Vishnoi
http://www.nephjc.com/news/sparsentan-protect

🎨Visual Abstract below by
Saumya Vishnoi
http://www.nephjc.com/news/2023/5/23/protect-study-on-sparsentan-in-igan-visual-abstract

Tweetorials covering the topic👇🏻
https://twitter.com/ckd_ce/status/1521464649069301760?
https://twitter.com/ckd_ce/status/1508757986868559875?s=20 s=20

8/10
Quote (Question) of the fortnight (decade really):

Will we ever have an answer? Unless we look systematically at the natural course/course on non-immunosuppressive or immunosuppressive therapy by doing serial biopsies? #NephJC
From Richard Glassock https://twitter.com/GlassockJ/status/1661315990389657600?s=20

7/10
#NephJC Chat consensus?

We need more data & accelerated approvals using surrogate end-points may not be a bad thing at all.

& Ahem, after rigorous trials & rounds of approval, there's the formidable next challenge- COST!💰

Very adequately put by @hswapnil (https://twitter.com/hswapnil/status/1661188894526717952?s=20)

Welcome to #TenTootNephJC
✳️10 toots to catch you up on the latest from #NephJC ✳️

At the end of May, NephJC discussed interim results📊from PROTECT trial on efficacy & safety of Sparsentan in IgAN.

New light✨on the horizon for IgAN yet?

Check out this flying summary in case you've missed the chat!
http://www.nephjc.com/news/sparsentan-protect

The #NephJC summer book club! http://www.nephjc.com/news/2022/5/28/summer-book-club-2023

From @fperrywilson

You heard it here,
Perry Wilson's book How Medicine Works and When It Doesn't is the choice for 2023 #NephJC Summer Book Club. Start reading now :) You are going to love it!

http://nephjc.com/news/2022/5/28/summer-book-club-2023

https://twitter.com/NephJC/status/1668039107300188162?s=20

Is there a selected #NephJC book for this summer?, cc: Dr. @hswapnil

Final thoughts

✳️RTX already standard of care for maintenance in AAV - consolidated by RITAZAREM

➡️Up next, the Preserve-Transplant Study - can HCO3 preserve graft function?

Join us on Tuesday/Wednesday for more🔥
https://pubmed.ncbi.nlm.nih.gov/36708734/

#TenTweetNephJC by
@sandyrvsdav brought to @Mastodon by @jmteakell #NephJC

9/10
I want more info:

✅ Check out the brilliant #NephJC summary from
@myasirbaloch & @nihal_hamary, which is accompanied by an intricately detailed slideset by @husamjz (a new #NephJC feature!!)
http://nephjc.com/news/ritazarem

✅ Visual abstract by @nikitap159
http://www.nephjc.com/news/2023/5/9/the-ritazarem-visual-abstract

8/10
#NephJC Quote of the fortnight!
https://twitter.com/gratefull080504/status/1656115254344966151?s=20

7/10
#NephJC Chat consensus?

1️⃣ RTX>AZA for preventing relapse in high-risk relapsing AAV

2️⃣ RTX safer

3️⃣ More data required on duration of effect of RTX

6/10 #NephJC
Give me something clever to say:
“After MAINRITSAN-1, these results were pretty expected! This trial attempted to further establish superiority of RTX as maintenance agent over AZA in relapsing AAV after RTX induction”
Here is how the 2 trials differed👇

5/10
A figure paints 1000 words #NephJC

4/10
1 tweet results

🔹n=85 each arm

🔹58 yrs, 91% white, 49% male, 28% high-dose steroids

🔹 RTX superior to AZA in preventing relapse
▶️HR 0.35 (95% CI 0.18-0.66) in maintenance period
▶️HR 0.45 (0.26-0.78) during further follow-up

🔹SAE: 44% in RTX vs 56% in AZA

#NephJC

Welcome to #TenTootNephJC

✳️10 toot #NephJC catch-up ✳️

🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab & Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis (AAV).

🌟Have we witnessed the ultimate triumph of Rituximab?